Orchid Pharma's New Antimicrobial Solutions Division Targets Rs 300 Crore Turnover

Orchid Pharma's new Antimicrobial Solutions division aims to achieve a turnover of Rs 300 crore in three years, tackling antimicrobial resistance in India. The division plans to partner with 2,500-3,000 hospitals and institutions and engage with the healthcare community across 13 cities by year-end.

Orchid Pharma's newly-formed antimicrobial solutions division is setting ambitious goals, targeting a turnover of up to Rs 300 crore within the next three years, according to a top company official. The division, bolstered by a sales force of 250, is combating the growing challenge of antimicrobial resistance in India.

Named Orchid AMS (Antimicrobial Solutions), the division plans to partner with around 2,500-3,000 hospitals and healthcare institutions over the next two to three years to implement effective antimicrobial stewardship programs (AMSPs). CEO Rajnish Rohatgi emphasized the severe challenges posed by easily available medications without prescriptions and the influx of antibiotics through poultry, fish, and crops.

Orchid AMS aims to cover approximately 3,000 hospitals and healthcare facilities in the next few years. It will engage with the healthcare community across 13 cities by the end of this year. Rohatgi revealed plans for a robust pipeline of new products, including Orblicef (Cefepime-Enmetazobactum), Ceftaroline, and Cefiderocol, to be introduced over the next two months to address this critical issue.

(With inputs from agencies.)